Tags

Type your tag names separated by a space and hit enter

Pharmacotherapy of obesity: Available medications and drugs under investigation.
Metabolism. 2019 03; 92:170-192.M

Abstract

Obesity is a chronic disease with a continuously rising prevalence that currently affects more than half a billion people worldwide. Energy balance and appetite are highly regulated via central and peripheral mechanisms, and weight loss triggers a homeostatic response leading to weight regain. Lifestyle and behavioral modifications are the cornerstones of obesity management; however, they often fail to achieve or sustain long-term weight loss. Pharmacotherapy added onto lifestyle modifications results in an additional, albeit limited, weight reduction. Regardless, this weight reduction of 5-10% conveys multiple cardiovascular and metabolic benefits. In this review, evidence on the food and drug administration (FDA)-approved medications, i.e., orlistat, lorcaserin, phentermine/topiramate, liraglutide and naltrexone/bupropion, is summarized. Furthermore, anti-obesity agents in the pipeline for potential future therapeutic use are presented.

Authors+Show Affiliations

Division of Endocrinology, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA 02215.Division of Endocrinology, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA 02215. Electronic address: ofarr@bidmc.harvard.edu.First Department of Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.Division of Endocrinology, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA 02215.Department of Medicine, Boston Medical Center, Boston, MA, 02118, United States of America.Division of Pediatric Newborn Medicine, Brigham and Women's Hospital/Harvard Medical School, Boston, MA 02215, United States of America.Division of Endocrinology, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA 02215; Section of Endocrinology, VA Boston Healthcare System, Harvard Medical School, Boston, MA, USA.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

30391259

Citation

Pilitsi, Eleni, et al. "Pharmacotherapy of Obesity: Available Medications and Drugs Under Investigation." Metabolism: Clinical and Experimental, vol. 92, 2019, pp. 170-192.
Pilitsi E, Farr OM, Polyzos SA, et al. Pharmacotherapy of obesity: Available medications and drugs under investigation. Metab Clin Exp. 2019;92:170-192.
Pilitsi, E., Farr, O. M., Polyzos, S. A., Perakakis, N., Nolen-Doerr, E., Papathanasiou, A. E., & Mantzoros, C. S. (2019). Pharmacotherapy of obesity: Available medications and drugs under investigation. Metabolism: Clinical and Experimental, 92, 170-192. https://doi.org/10.1016/j.metabol.2018.10.010
Pilitsi E, et al. Pharmacotherapy of Obesity: Available Medications and Drugs Under Investigation. Metab Clin Exp. 2019;92:170-192. PubMed PMID: 30391259.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pharmacotherapy of obesity: Available medications and drugs under investigation. AU - Pilitsi,Eleni, AU - Farr,Olivia M, AU - Polyzos,Stergios A, AU - Perakakis,Nikolaos, AU - Nolen-Doerr,Eric, AU - Papathanasiou,Aimilia-Eirini, AU - Mantzoros,Christos S, Y1 - 2018/11/01/ PY - 2018/09/10/received PY - 2018/10/13/revised PY - 2018/10/23/accepted PY - 2018/11/6/pubmed PY - 2019/11/26/medline PY - 2018/11/5/entrez KW - Liraglutide KW - Lorcaserin KW - Naltrexone/bupropion KW - Obesity KW - Orlistat KW - Personalized therapy phentermine/topiramate SP - 170 EP - 192 JF - Metabolism: clinical and experimental JO - Metab. Clin. Exp. VL - 92 N2 - Obesity is a chronic disease with a continuously rising prevalence that currently affects more than half a billion people worldwide. Energy balance and appetite are highly regulated via central and peripheral mechanisms, and weight loss triggers a homeostatic response leading to weight regain. Lifestyle and behavioral modifications are the cornerstones of obesity management; however, they often fail to achieve or sustain long-term weight loss. Pharmacotherapy added onto lifestyle modifications results in an additional, albeit limited, weight reduction. Regardless, this weight reduction of 5-10% conveys multiple cardiovascular and metabolic benefits. In this review, evidence on the food and drug administration (FDA)-approved medications, i.e., orlistat, lorcaserin, phentermine/topiramate, liraglutide and naltrexone/bupropion, is summarized. Furthermore, anti-obesity agents in the pipeline for potential future therapeutic use are presented. SN - 1532-8600 UR - https://www.unboundmedicine.com/medline/citation/30391259/Pharmacotherapy_of_obesity:_Available_medications_and_drugs_under_investigation_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0026-0495(18)30228-2 DB - PRIME DP - Unbound Medicine ER -